Early-stage endometrial cancer beaten by low-cost birth control device

Researchers believe that an effective treatment for early-stage endometrial cancer for some groups of patients already exists: a typical birth control device. Oncologists and surgeons at Georgia Health Sciences University Cancer Center determined that an intrauterine contraceptive device that releases the progestin levonorgestrel was particularly effective in morbidly obese women and high-risk surgery patients. They found that the inexpensive device successfully reversed abnormal cell growth in patients who had early-stage endometrioid adenocarcinoma (an endometrial cancer subtype) and patients with a thickening of the uterine lining, which is often a precursor to cancer. Release

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.